Which systemic condition is treated by the combination of alogliptin and pioglitazone?

Prepare for the Dentalcare Case Studies Exam. Study with engaging flashcards and multiple choice questions, complete with hints and explanations. Get exam-ready effectively!

Multiple Choice

Which systemic condition is treated by the combination of alogliptin and pioglitazone?

Explanation:
Both alogliptin and pioglitazone are antidiabetic medications used to improve glucose control in type 2 diabetes. Type 2 diabetes involves insulin resistance and gradually reduced insulin effectiveness. Alogliptin is a DPP-4 inhibitor that raises incretin hormones, boosting glucose-dependent insulin release and lowering glucagon after meals. Pioglitazone is a TZD that activates PPAR-γ, enhancing insulin sensitivity in muscle and fat and reducing hepatic glucose production. Using them together addresses two major problems in type 2 diabetes—impaired insulin action and inadequate insulin response—whereas they’re not used to treat type 1 diabetes (autoimmune beta-cell destruction) or primarily treat hypertension or hyperlipidemia.

Both alogliptin and pioglitazone are antidiabetic medications used to improve glucose control in type 2 diabetes. Type 2 diabetes involves insulin resistance and gradually reduced insulin effectiveness. Alogliptin is a DPP-4 inhibitor that raises incretin hormones, boosting glucose-dependent insulin release and lowering glucagon after meals. Pioglitazone is a TZD that activates PPAR-γ, enhancing insulin sensitivity in muscle and fat and reducing hepatic glucose production. Using them together addresses two major problems in type 2 diabetes—impaired insulin action and inadequate insulin response—whereas they’re not used to treat type 1 diabetes (autoimmune beta-cell destruction) or primarily treat hypertension or hyperlipidemia.

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy